JP2010523559A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523559A5
JP2010523559A5 JP2010502079A JP2010502079A JP2010523559A5 JP 2010523559 A5 JP2010523559 A5 JP 2010523559A5 JP 2010502079 A JP2010502079 A JP 2010502079A JP 2010502079 A JP2010502079 A JP 2010502079A JP 2010523559 A5 JP2010523559 A5 JP 2010523559A5
Authority
JP
Japan
Prior art keywords
phenoxy
polymorph
diethylamine
chloro
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010502079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/003325 external-priority patent/WO2008123914A1/en
Publication of JP2010523559A publication Critical patent/JP2010523559A/ja
Publication of JP2010523559A5 publication Critical patent/JP2010523559A5/ja
Pending legal-status Critical Current

Links

JP2010502079A 2007-04-05 2008-03-12 ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 Pending JP2010523559A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92196407P 2007-04-05 2007-04-05
US92578607P 2007-04-23 2007-04-23
PCT/US2008/003325 WO2008123914A1 (en) 2007-04-05 2008-03-12 Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Publications (2)

Publication Number Publication Date
JP2010523559A JP2010523559A (ja) 2010-07-15
JP2010523559A5 true JP2010523559A5 (enExample) 2011-03-31

Family

ID=39469930

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010502079A Pending JP2010523559A (ja) 2007-04-05 2008-03-12 ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態

Country Status (11)

Country Link
US (2) US7884219B2 (enExample)
EP (1) EP2144883A1 (enExample)
JP (1) JP2010523559A (enExample)
AR (1) AR065896A1 (enExample)
CA (1) CA2681864A1 (enExample)
CL (1) CL2008000987A1 (enExample)
PA (1) PA8775601A1 (enExample)
PE (1) PE20090808A1 (enExample)
TW (1) TW200900384A (enExample)
UY (1) UY31004A1 (enExample)
WO (1) WO2008123914A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681864A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
JP5805646B2 (ja) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー アルツハイマー病の治療のための置換イミダゾール誘導体
NZ705813A (en) * 2012-10-05 2018-02-23 Vtv Therapeutics Llc Treatment of mild and moderate alzheimer’s disease
US9717710B2 (en) * 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
CN103726005A (zh) * 2012-10-16 2014-04-16 深圳富泰宏精密工业有限公司 珐琅涂层的制造方法及其制品
WO2019190822A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
US11648235B1 (en) 2022-12-30 2023-05-16 Cantex Pharmaceuticals, Inc. Treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
CA2681864A1 (en) * 2007-04-05 2008-10-16 Transtech Pharma, Inc. Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine

Similar Documents

Publication Publication Date Title
JP2010523559A5 (enExample)
JP6681989B2 (ja) ボリコナゾール中間体及びボリコナゾールの合成方法
Sun et al. A green luminescent 1-D helical tubular dipyrazol-bridged cadmium (II) complex: a coordination tube included in a supramolecular tube
Sangeetha et al. Vibrational, DFT, and thermal analysis of 2, 4, 6-triamino-1, 3, 5-triazin-1-ium 3-(prop-2-enoyloxy) propanoate acrylic acid monosolvate monohydrate
JP2016513060A5 (enExample)
CN104447804B (zh) 间苯双三唑Cu-三氟甲磺酸配合物及其制备方法与应用
CN103242193B (zh) 一种羟肟化杯[6]芳烃高效铀萃取剂的制备及其用途
WO2007047838A2 (en) Process for preparing olmesartan medoxomil
WO2010010454A2 (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
EP2809665A1 (en) Process for the preparation of vilazodone or its pharmaceutically acceptable salts
JP6041985B2 (ja) 結晶型ｔ−ブチル２−［（４Ｒ，６Ｓ）−６−ホルミル−２，２−ジメチル−１，３−ジオキサン−４−イル］アセテート及びその製造方法
CN103755644B (zh) 化合物、其合成及用其合成双UPy取代化合物的方法
CN104370900B (zh) 一种盐酸阿罗洛尔的制备方法
CN105777617B (zh) 色瑞替尼的合成中间体及其制备方法
CN102531970B (zh) 碳酰肼及其快速合成方法
EP2225209A1 (en) Process for the preparation of 5-(2-ethyl-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof
JP2012524736A5 (enExample)
Morshedi et al. Mixed halide/oxoanion-templated frameworks
WO2017131218A1 (ja) アジルサルタン及びその製造方法
CN103664901B (zh) 一种苯甲酸利扎曲坦制备方法
CN105348284A (zh) 一种伊曲茶碱新的合成方法
JP7177796B2 (ja) アジルサルタンａ型結晶の製造方法
JP5575783B2 (ja) トリフェニルメタン保護基の除去方法
CN103319472B (zh) 一种伊潘立酮的制备方法
CN106749202A (zh) 一种立福康唑中间体的制备方法